Caribou Biosciences, Inc. (CRBU)

NASDAQ: CRBU · Real-Time Price · USD

1.900

-0.040 (-2.06%)

At close: Dec 5, 2025, 4:00 PM EST

1.895

-0.005 (-0.29%)

After-hours: Dec 5, 2025, 7:36 PM EST

Caribou Biosciences Employees

Caribou Biosciences had 147 employees as of December 31, 2024. The number of employees decreased by 11 or -6.96% compared to the previous year.

Employees

147

Change (1Y)

-11

Growth (1Y)

-6.96%

Revenue / Employee

$63,231

Profits / Employee

-$1,068,891

Market Cap

177.59M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	147	-11	-6.96%
Dec 31, 2023	158	21	15.33%
Dec 31, 2022	137	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

CRBU News

4 days ago - Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 - GlobeNewsWire
23 days ago - Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
4 weeks ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
4 weeks ago - Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
4 weeks ago - Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - GlobeNewsWire
4 weeks ago - Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - GlobeNewsWire
4 weeks ago - Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - GlobeNewsWire
3 months ago - Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference - GlobeNewsWire